Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Cognitive Function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of hippocampal-sparing whole brain radiotherapy (WBRT) on neurocognitive function decline in patients with brain metastases. It aims to determine whether avoiding radiation exposure to the hippocampus can mitigate cognitive decline associated with WBRT. Patients with confirmed non-hematopoietic malignancies and limited brain metastases will be treated with this specialized radiotherapy approach. The study will assess cognitive outcomes compared to traditional WBRT methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with pathologically-confirmed non-hematopoietic malignancy who are referred for therapeutic or prophylactic WBRT
* Good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky Score (KPS) at least 70 %
* The number and extent of brain metastatic lesions should be no more than three metastatic foci with a greatest diameter no more than 4 cm

Exclusion Criteria:

* Patients with MRI-identified metastasis within 5 mm perihippocampally
* Clinical suspicion of leptomeningeal spreading
* History of prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons

Where it's running

• Chang Gung Memorial Hospital
  Taoyuan, Taiwan Recruiting

Study contacts

• Study coordinator: Chi-Cheng Chuang, M.D.
• Email: ccc2915@cgmh.org.tw
• Phone: +886-33281200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive stepped care program for adults with brain metastases

  This project will test whether routine screening plus a stepped program of education and tailored cognitive support can help adults with brain metastases manage thinking and memory problems.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07355348

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• What causes vulnerability in older adults with serious diseases and how it affects care decisions

  This study tests how often vulnerability factors appear in older adults with serious illnesses and how these factors influence treatment timing, survival, and quality of life.

  Recruiting Tampere University Hospital · Tampere · NCT07740239

• Omitting brain metastasis radiation after tumor removal when CNS-active therapy is used

  This pilot study tests whether patients with resected brain metastases from melanoma or NSCLC can skip post-operative brain radiation while receiving CNS-active systemic therapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07655583

• EarlyFDG PET after Radiotherapy to See Brain Metastases and Radionecrosis

  This study tests whether a short FDG-PET scan after radiotherapy can help tell apart radionecrosis from recurring brain metastases in adults.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07632092

• Sac-TMT plus bevacizumab in TNBC with brain metastases

  This phase II, single-arm study tests whether Sac-TMT combined with bevacizumab can help people with triple-negative breast cancer and brain metastases.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07623577

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.